Acute Respiratory Distress Syndrome Market
DelveInsight, a Healthcare consulting and
Market Research company, estimated that there were total 815,490 Acute
Respiratory Distress Syndrome incident cases in the 7MM in the year 2017.
Moreover, the Acute Respiratory Distress Syndrome incidence is bound to
increase, however, mortality rates due to the infection are on decrease.
Acute Respiratory Distress Syndrome (ARDS)
is characterized by the development of acute dyspnea and hypoxemia as a result
of provoking events such as trauma, sepsis, drug overdose, massive transfusion,
acute pancreatitis, or aspiration. The most common cause of ARDS, however, as
studies revealed is an infection due to sepsis
ARDS is a life-threatening disease because
the body’s organs fail to receive sufficient amount of oxygen due to the excess
build-up of fluid in the lungs and stop working efficiently.
DelveInsight surveys revealed that the
Acute Respiratory Distress Syndrome treatment, primarily is supportive
including invasive mechanical ventilation with lung protective strategies in
nature, and eases off the intensity of the symptoms.
However, long term incubation of the
ventilator puts the patient at risk of developing several complications like
ventilator-associated pneumonia, delirium and critical illness myopathy and
neuropathy.
Other Acute Respiratory Distress Syndrome
treatment options, which the patients with ARDS are generally subjected to,
include supplemental oxygen, prone positioning, use of paralytics, fluid
management and a technique called positive end expiratory pressure (PEEP) to
help push the fluid
People with ARDS find themselves unable to
fight lung infections, they may develop during the course of the illness. That
is why antibiotics are prescribed to fight infection.
Further, the use of adjunctive therapies in
Acute respiratory distress syndrome treatment market in patients on day 1 or 2
was relatively low but increased with ARDS severity. Continuous neuromuscular
blocking agents, high-dose steroids, and recruitment manoeuvres are the most
frequently used adjuncts, as observed by DelveInsight.
The absence of standard therapies in Acute
Respiratory Distress Syndrome treatment market, and proper diagnostics
methods has result in an increase in the global Acute Respiratory Distress Syndrome
burden. The ARDS
incidence calculation is not easy as the trends seems to differ based on
different geographies.
Despite the limitations in the present
Acute respiratory distress syndrome, the living-quality ARDS patient pool has
increased attributed to a better understanding of the etiology and
pathophysiology of the disorder.
The dynamics of ARDS market is anticipated
to change during the forecast period, owing to the expected launch of Acute
respiratory distress syndrome emerging therapies. Key players in the ARDS market
are Faron Pharmaceuticals, Implicit Bioscience, Techpool Bio-Pharma, BioMarck
Pharmaceuticals, Athersys, Apeptico Forschung und Entwicklung GmbH, Savara,
Cynata therapeutics, and others.
Two emerging therapies, in the late
clinical development, are focused on the ARDS treatment and hence are expected
to create a significant impact on Acute respiratory distress syndrome market
size.
The companies such as Traumakine (Faron
Pharmaceuticals) and BIO11006 (BioMarck pharmaceuticals) and are expected to
launch during the forecast period [2018-2027] and impact significantly in the
upcoming Acute respiratory distress syndrome market.
Comments
Post a Comment